title: [Do controlled ovarian hyperstimulations and cryopreservations promote recurrences after breast cancer?]
abstract: The objective of this review was to identify recurrences (ipsilateral, contralateral, metastases and deaths) occurring after controlled ovarian hyperstimulation (COH) or cryopreservation of ovarian tissue (CPTO) for patients treated for a breast cancer.
  
  
  METHODS
  We performed a bibliographical research through the Pubmed/Medline database, including all the references from January 2006 until September 2016, in French or in English, after exclusion of animal studies. The keywords association "breast neoplasms", "fertility preservation", "reproductive techniques", "ovarian cryopreservation" and "in vitro fertilization" allowed the selection of 852 publications among which only 6 were selected because they included data on recurrence and long term follow up. Four publications involved HSC (3 before breast cancer treatment and 1 after) and 2 concerned CPTO with re-implantation.
  
  
  RESULTS
  This analysis has not shown increasing of breast recurrences after HSC and CPTO. However, results were not statistically significant, due to several biases in particular heterogeneousness of the groups of patients.
  
  
  CONCLUSIONS
  A survey of patients who used fertility preservation or assisted reproductive technologies after breast cancer would be helpful to better estimate their oncological risk.
authors.affiliation: Unité de sénologie, hôpital Hautepierre, hôpitaux universitaires de Strasbourg, CHRU, 1, avenue Molière, 67200 Strasbourg, France. Electronic address: MarieLaure.BERGAMINI@chru-strasbourg.fr.
authors.forename: M-L
authors.initials: ML
authors.lastname: Bergamini
authors.affiliation: Unité d'oncogénétique moléculaire, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg, France; Unité d'oncogénétique clinique : évaluation familiale et suivi, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg, France.
authors.forename: C M
authors.initials: CM
authors.lastname: Maugard
authors.affiliation: Unité de sénologie, hôpital Hautepierre, hôpitaux universitaires de Strasbourg, CHRU, 1, avenue Molière, 67200 Strasbourg, France; IGBMC, institut de génétique et de biologie moléculaire et cellulaire, biologie du cancer, CNRS UMR 7104, Inserm U964, université de Strasbourg, 67400 Illkirch, France.
authors.forename: C
authors.initials: C
authors.lastname: Mathelin
mesh_terms: D001943:Breast Neoplasms / Q000628:therapy*; D015925:Cryopreservation; D005260:Female; D059247:Fertility Preservation / Q000009:adverse effects* / Q000379:methods; D005307:Fertilization in Vitro; D006801:Humans; D016239:MEDLINE; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D010053:Ovary; D010062:Ovulation Induction / Q000009:adverse effects*; D027724:Reproductive Techniques, Assisted / Q000009:adverse effects; D012307:Risk Factors
keywords: Breast cancer; Cancer du sein; Controlled ovarian hyperstimulation; Cryopreservation of ovarian tissue; Cryopréservation de tissu ovarien; Fertility preservation; Préservation de fertilité; Recurrence; Récidive; Stimulation ovarienne contrôlée